This page is funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this page is not medical advice and does not replace independent medical judgment.

This is a video synopsis/summary of an OncLive Insights involving Lipika Goyal, MD; Chaundra Bishop; R. Katie Kelley, MD; and Caroline Kuhlman, NP.

Kelley provided background on cholangiocarcinoma (CCA), a type of biliary tract cancer that makes up 5% to 10% of primary liver cancers. She explained the anatomy related to CCA, including intrahepatic CCA (IH-CCA) (within the bile ducts of the liver), perihilar/hilar CCA (at the liver entrance), and extrahepatic/distal CCA (below the gallbladder). Gallbladder carcinoma is also included in the CCA family. Kelley contrasted CCA and hepatocellular carcinoma, the most common form of liver cancer. While they can share common progenitor cells, CCAs have different mutations, cell surface proteins, and cellular function.

Goyal noted exciting progress in new treatments for CCA, with the first FDA approval of an FGFR inhibitor in 2020. More drugs are in development, bringing more hope for patients.

Bishop, a patient diagnosed with CCA 7 years ago, expressed excitement about the new FGFR inhibitor treatments beyond standard chemotherapy, as more options are now available.

The panelists agreed CCA treatment has progressed rapidly in recent years. Goyal stated there is more hope for CCA patients now compared to 5 to 10 years ago.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.